Bacteriotherapy - ExeGi Pharma
Alternative Names: Live Biotherapeutic - ExeGi Pharma; SivoBiome™ Live Biotherapeutic - ExeGi PharmaLatest Information Update: 28 Aug 2023
At a glance
- Originator ExeGi Pharma
- Class Antidiarrhoeals; Antivirals; Bacteria; Probiotics
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections; Diarrhoea
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy) in Italy (PO)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Diarrhoea(Combination therapy) in Italy (PO)
- 16 Jul 2020 Safety and efficacy data from a phase I trial in COVID-2019 infections and diarrhoea released by ExeGi Pharma